drugset / Trial / NCT00659971
Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine the optimal dose of PAC113 mouthrinse for treatment of oral candidiasis in HIV seropositive patients.
Timeline
- Start
- 2008-01
- Primary completion
- 2008-06
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PAC113 | Unknown | 0.0375 % | — |
| Subject | PAC113 | Unknown | 0.075 % | — |
| Subject | PAC113 | Unknown | 0.15 % | — |